Erica P. Gunderson, PhD, MS, MPH, offers perspective on the current state of gestational diabetes management as well as avenues for improving current diagnostic and management standards.
For all the attention that has been brought to the ongoing diabetes epidemic in recent years, many endocrinologists and other members of the diabetes care team argue forms of diabetes outside of type 2 diabetes are still overlooked and underrecognized.
A recent article published in JAMA, which found rates of gestational diabetes have been increasing in the US across all ethnicities and racial subgroups over the last 20 years, highlighted this very fact. With presence of diabetes increasing the risk for other cardiometabolic comorbidities, identification of avenues for improving diagnosis and management of gestational diabetes could have a profound impact on the disease state as a whole.
During the Metabolic Institute of America’s (TMIOA) 5th Heart in Diabetes sessions in New York, NY, Erica P. Gunderson, PhD, MS, MPH, a senior research scientist in the Kaiser Permanente Northern California Division of Research, led a presentation centered around gestational diabetes, insulin resistance, and prognostic value of coronary artery calcium in women based on data from analyses of the CARDIA study.
To learn more about the management of gestational diabetes in 2021 and her presentation, our sister publication HCPLive sat down with Gunderson following her presentation at the conference. Learn more about her perspective in the video below.